Immucell (ICCC) Retained Earnings (2010 - 2026)
Immucell's (ICCC) quarterly Retained Earnings came in at -$15.2 million in Q4 2025, down 7.34% YoY from -$16.4 million in Q4 2024, and down 23.06% on a QoQ basis from -$12.4 million in Q3 2025.
Immucell (ICCC) Retained Earnings (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Retained Earnings data on file, last reported at -$15.2 million in Q4 2025.
- Quarterly Retained Earnings fell 7.34% year-over-year to -$15.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.2 million (down 7.34% YoY) and the FY2025 annual result came in at -$15.2 million, down 7.34% from the prior year.
- Retained Earnings declined to -$15.2 million in Q4 2025, from -$12.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $36.2 million in Q2 2023 to a low of -$15.2 million in Q4 2025.
- A 5-year average of -$2.8 million and a median of -$9.7 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 1041.9% — and 2023, when it plunged 165.01%.
- Tracing ICCC's Retained Earnings over 5 years: stood at -$3.7 million in 2021, then plunged by 66.7% to -$6.2 million in 2022, then slumped by 92.65% to -$12.0 million in 2023, then declined by 17.96% to -$14.2 million in 2024, then fell by 7.34% to -$15.2 million in 2025.
- The last three Retained Earnings figures came in at -$15.2 million (Q4 2025), -$12.4 million (Q3 2025), and -$12.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | -11.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.43 Mn |
| Dec 31, 2025 | -15.20 Mn |
| Sep 30, 2025 | -12.35 Mn |
| Jun 30, 2025 | -12.21 Mn |
| Mar 31, 2025 | -12.72 Mn |
| Dec 31, 2024 | -14.16 Mn |
| Sep 30, 2024 | -14.68 Mn |
| Jun 30, 2024 | -13.98 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Dec 31, 2023 | -12.01 Mn |
| Sep 30, 2023 | -10.87 Mn |
| Jun 30, 2023 | 36.15 Mn |
| Mar 31, 2023 | -8.55 Mn |
| Dec 31, 2022 | -6.23 Mn |
| Sep 30, 2022 | 35.91 Mn |
| Jun 30, 2022 | 35.83 Mn |
| Mar 31, 2022 | -3.23 Mn |
| Dec 31, 2021 | -3.74 Mn |
| Sep 30, 2021 | -3.81 Mn |
| Jun 30, 2021 | -3.96 Mn |